I promise

"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Wednesday, September 26, 2018

UT Researchers Awarded Nearly Half a Million for Breast Cancer Research

"I was quoted in the below article on the Triple Negative Breast Research here in Toledo at UTMC that was awarded close to half a million in a national grant from Susan G. Komen. Thank you Dr. Amit Tawari for including me on your research team as your patient advocate mentor for this. I hope this research is the answer that all us TNBC survivors have been longing for." - Melissa Paskvan


Scientific breakthrough in Triple Negative Breast Cancer research being conducted at the University of Toledo: 
https://www.toledoblade.com/local/education/2018/09/25/susan-komen-donates-ut-half-million-breast-cancer-research/stories/20180924231

Total Pageviews



"click image to link"